1. Home
  2. KNDI vs ALXO Comparison

KNDI vs ALXO Comparison

Compare KNDI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNDI
  • ALXO
  • Stock Information
  • Founded
  • KNDI 2002
  • ALXO 2015
  • Country
  • KNDI China
  • ALXO United States
  • Employees
  • KNDI N/A
  • ALXO N/A
  • Industry
  • KNDI Auto Manufacturing
  • ALXO Biotechnology: Pharmaceutical Preparations
  • Sector
  • KNDI Consumer Discretionary
  • ALXO Health Care
  • Exchange
  • KNDI Nasdaq
  • ALXO Nasdaq
  • Market Cap
  • KNDI 101.7M
  • ALXO 93.7M
  • IPO Year
  • KNDI N/A
  • ALXO 2020
  • Fundamental
  • Price
  • KNDI $1.15
  • ALXO $1.54
  • Analyst Decision
  • KNDI
  • ALXO Strong Buy
  • Analyst Count
  • KNDI 0
  • ALXO 6
  • Target Price
  • KNDI N/A
  • ALXO $3.30
  • AVG Volume (30 Days)
  • KNDI 98.8K
  • ALXO 441.2K
  • Earning Date
  • KNDI 11-17-2025
  • ALXO 11-07-2025
  • Dividend Yield
  • KNDI N/A
  • ALXO N/A
  • EPS Growth
  • KNDI N/A
  • ALXO N/A
  • EPS
  • KNDI N/A
  • ALXO N/A
  • Revenue
  • KNDI $104,035,613.00
  • ALXO N/A
  • Revenue This Year
  • KNDI N/A
  • ALXO N/A
  • Revenue Next Year
  • KNDI N/A
  • ALXO N/A
  • P/E Ratio
  • KNDI N/A
  • ALXO N/A
  • Revenue Growth
  • KNDI N/A
  • ALXO N/A
  • 52 Week Low
  • KNDI $0.89
  • ALXO $0.40
  • 52 Week High
  • KNDI $1.81
  • ALXO $2.27
  • Technical
  • Relative Strength Index (RSI)
  • KNDI 37.27
  • ALXO 47.09
  • Support Level
  • KNDI $1.21
  • ALXO $1.51
  • Resistance Level
  • KNDI $1.29
  • ALXO $1.90
  • Average True Range (ATR)
  • KNDI 0.05
  • ALXO 0.13
  • MACD
  • KNDI -0.01
  • ALXO -0.04
  • Stochastic Oscillator
  • KNDI 0.00
  • ALXO 12.20

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: